Get access to our best features
Get access to our best features
Published 5 months ago

FDA approves cure for sickle cell disease, the first treatment to use gene-editing tool CRISPR

  • The U.S. FDA has approved Casgevy, the country's first gene-editing treatment, for sickle cell disease patients aged 12 and older.
  • Casgevy, developed by Vertex Pharmaceuticals and CRISPR Therapeutics, uses CRISPR technology to edit genes and treat the disease.
  • Analysts raise concerns about the high cost, complexity, and limited availability of the treatment.
Insights by Ground AI
Does this summary seem wrong?

0 Articles

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 65% of the sources are Center
65% Center

To view factuality data please Upgrade to Premium


To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)